FNP122, edaravone in oral form, enters Phase 3 extension trial
A Phase 3 clinical trial that’s testing FNP122, Ferrer’s oral formulation of edaravone, in people with amyotrophic…
Articles by Patricia Inácio, PhD
Wearable Cognixion ONE Axon named FDA breakthrough device
Cognixion’s flagship device Cognixion ONE Axon, a product designed to improve communication in people with severe motor impairments,…
Apellis stops dosing of pegcetacoplan in ALS trial after data review
Apellis Pharmaceuticals has discontinued treatment with pegcetacoplan (APL-2), its investigational therapy for amyotrophic lateral sclerosis (ALS), in…
Radicava ORS, oral form of edaravone, available to US veterans
Radicava ORS, an oral formulation of Radicava (edaravone), is now available to U.S. veterans living with amyotrophic lateral sclerosis (ALS),…
Kadimastem asks for FDA to clear new AstroRx clinical trial
Kadimastem is planning a Phase 2a clinical trial to test if repeat dosing of AstroRx, its investigational therapy for…
Higher ‘Good’ Cholesterol Linked to Worse ALS Survival Rate
Elevated levels of high-density lipoprotein (HDL) — commonly called the “good” cholesterol — are significantly associated with a…
Partnership Aims to Treat ALS by Restoring Mitochondria, Cell Energy
MitoSense and the Centre for Transplantation Technology at Uppsala University are collaborating to harness the power of mitochondria…
Biomarkers May Determine ALS Progression, Edaravone Response
Continuous monitoring of certain biomarkers in people with amyotrophic lateral sclerosis (ALS) may inform about the risk of disease…
FDA Clears ALS Clinical Study of Cellenkos Treg Cell Therapy CK0803
Cellenkos will soon launch two Phase 1 clinical trials to investigate the safety and potential efficacy of its regulatory…
Aquinnah Partners With Roche to Develop Small Molecules to Treat ALS
Aquinnah Pharmaceuticals has partnered with Roche to further develop its brain-penetrating, oral small molecules for the treatment of…